We use cookies to help provide you with the best possible online experience. Learn more

Financial Reports

RaySearch Laboratories AB (publ) Interim Report January 1 – March 31, 2010

JANUARY 1 – MARCH 31, 2010 • Net sales for the period totaled SEK 28.1 M (16.9) • Profit after tax was SEK 8.2 M (7.3), corresponding to earnings per share of SEK 0.24 (0.21) • Operating profit totaled SEK 11.2 M (9.9) • Cash flow was a negative SEK 1.8 M (positive: 8.7) • RaySearch received FDA 510(k) clearance for RayStation® in the US SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD • The collaboration agreement with Varian was expanded in April “The year 2010 started favorably with a strong first quarter. Thanks to several key product launches toward year-end 2009, revenues increased by 66 percent and the number of licenses sold almost doubled. This means that the quarterly revenues were the second highest ever for RaySearch,” says Johan Löf, CEO of RaySearch. “It was an important milestone to receive 510(k) clearance from the FDA for our treatment planning system RayStation®. This means that we can now market the system in the US”, concludes Johan Löf.